Advanced Nanomedicine: Redefining Therapeutic Paradigms for Inflammatory Bowel Disease

被引:22
|
作者
Zhang, Yinfeng [1 ,2 ]
Wang, Tingting [2 ]
Sun, Meng [3 ]
Song, Yueyue [3 ]
Huang, Xinyuan [1 ]
Zhang, Shutian [1 ]
Yang, Jun [4 ]
Zhang, Jinfeng [3 ]
机构
[1] Capital Med Univ, Beijing Friendship Hosp, Natl Clin Res Ctr Digest Dis, Dept Gastroenterol,Beijing Key Lab Precancerous Le, Beijing 100050, Peoples R China
[2] Capital Med Univ, Beijing Friendship Hosp, Int Med Ctr, Beijing 100050, Peoples R China
[3] Beijing Inst Technol, Sch Life Sci, Key Lab Mol Med & Biotherapy, Beijing 100081, Peoples R China
[4] Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China
基金
中国国家自然科学基金;
关键词
gut microbiota; inflammatory bowel disease (IBD); macrophage polarization; nanotherapeutics; reactive oxygen species (ROS); REACTIVE OXYGEN METABOLITES; ULCERATIVE-COLITIS; GUT MICROBIOTA; TNF-ALPHA; INTESTINAL ORGANOIDS; DELIVERY; NANOPARTICLES; THERAPIES; IMMUNITY; IBD;
D O I
10.1002/adhm.202300069
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Inflammatory bowel disease (IBD), a chronic and recurrent gastrointestinal inflammatory disorder with a variety of painful clinical manifestations and an increased risk of cancerization or death, has become an emerging challenge to global healthcare due to its rapidly increasing incidence. At present, there is no efficient cure against IBD because of the elusive etiology and pathogenesis of IBD. Therefore, the development of alternative therapeutic strategies with positive clinical efficacy and reduced side effects is urgently needed. In recent years, the great prosperity of nanomedicine promoted by a variety of advanced nanomaterials is redefining more attractive and promising therapeutic strategies for IBD owing to their advantages in the physiological stability, bioavailability, and targeting of inflammatory sites. In this review, firstly the basic characteristics of healthy and inflammatory intestinal microenvironments are presented. Then, different administration routes and targeting strategies of nanotherapeutics for IBD treatment are reviewed. Subsequently, a specific focus is placed on the introduction of nanotherapeutic treatments based on different IBD pathogenesis. Finally, some future challenges and perspectives of the currently developed nanomedicines for IBD treatment are provided. It is believed that the above topics will attract researchers from various fields including medicine, biological sciences, materials, chemistry and pharmaceutics.
引用
收藏
页数:21
相关论文
共 50 条
  • [21] Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease
    Yue, Bei
    Yu, Zhi-Lun
    Lv, Cheng
    Geng, Xiao-Long
    Wang, Zheng-Tao
    Dou, Wei
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (30) : 4378 - 4393
  • [22] Classification of Nanomaterial Drug Delivery Systems for Inflammatory Bowel Disease
    Wang, Haichen
    Zhou, Feifei
    Shen, Mengdan
    Ma, Ronglin
    Yu, Qiang
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2025, 20 : 1383 - 1399
  • [23] The Gut Microbiota in Inflammatory Bowel Disease
    Qiu, Peng
    Ishimoto, Takatsugu
    Fu, Lingfeng
    Zhang, Jun
    Zhang, Zhenyong
    Liu, Yang
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [24] Probiotics in the Treatment of Inflammatory Bowel Disease
    Guandalini, Stefano
    Sansotta, Naire
    PROBIOTICS AND CHILD GASTROINTESTINAL HEALTH: ADVANCES IN MICROBIOLOGY, INFECTIOUS DISEASES AND PUBLIC HEALTH, VOL 10, 2019, 1125 : 101 - 107
  • [25] Analysis of nanomedicine applications for inflammatory bowel disease: structural and temporal dynamics, research hotspots, and emerging trends
    Jiang, Hong-Yu
    Shao, Bo
    Wang, Hong-Da
    Zhao, Wen-Qi
    Ren, Shao-Hua
    Xu, Yi-Ni
    Liu, Tong
    Sun, Cheng-Lu
    Xiao, Yi-Yi
    Li, Yi-Cheng
    Chen, Qiang
    Zhao, Peng-Yu
    Yang, Guang-Mei
    Liu, Xu
    Ren, Yu-Fan
    Wang, Hao
    FRONTIERS IN PHARMACOLOGY, 2025, 15
  • [26] Inflammatory bowel disease in India-changing paradigms
    Ray, Gautam
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2011, 26 (05) : 635 - 644
  • [27] Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities
    Iliev, Iliyan D.
    Ananthakrishnan, Ashwin N.
    Guo, Chun-Jun
    NATURE REVIEWS MICROBIOLOGY, 2025,
  • [28] Changing treatment paradigms for the management of inflammatory bowel disease
    Im, Jong Pil
    Ye, Byong Duk
    Kim, You Sun
    Kim, Joo Sung
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2018, 33 (01) : 28 - 35
  • [29] Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease
    Hidetoshi Takedatsu
    Keiichi Mitsuyama
    Takuji Torimura
    World Journal of Gastroenterology, 2015, (40) : 11343 - 11352
  • [30] Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease
    Takedatsu, Hidetoshi
    Mitsuyama, Keiichi
    Torimura, Takuji
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (40) : 11343 - 11352